The origin and dynamics of cellular heterogeneity vary across lineage subtypes of castrate resistant prostate cancer
Michael L. Beshiri(National Cancer Institute), Kathleen Kelly(National Cancer Institute)
Cited by 3
Related Papers
Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models
|Journal of Clinical Investigation|2023|28